Leflunomide, a novel immunomodulating drug, inhibits homotypic adhesion of peripheral blood and synovial fluid mononuclear cells in rheumatoid arthritis

Inflammation Research

Volumn 45, Issue 11, 1996, Pages 550-556

  Dimitrijevic, M ^a   Bartlett, R R ^b  

^a UNIVERSITY OF BELGRADE   (Serbia)

^b SANOFI   (France)

Author keywords

Homotypic adhesion; Leflunomide; Rheumatoid arthritis

Indexed keywords

ANTIGEN; CD69 ANTIGEN; CD71 ANTIGEN; HLA DR ANTIGEN; IMMUNOMODULATING AGENT; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 2 RECEPTOR; LEFLUNOMIDE; MONOCLONAL ANTIBODY; TERIFLUNOMIDE;

ANTIGEN EXPRESSION; ARTICLE; BLOOD CELL; CELL ADHESION; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; FEMALE; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; IMMUNOMODULATION; MALE; MONONUCLEAR CELL; RHEUMATOID ARTHRITIS; SYNOVIAL FLUID;

EID: 0029904990     PISSN: 10233830     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02342226     Document Type: Article

References (40)

1. Bartlett RR, Schleyerbach R. Immunopharmcological profile of a novel isoxazol derivate, HWA 486, with potential antirheumatic activity. I. Disease modifying action on adjuvant arthritis of the rat. Int J Immunopharm 1985;7:7-18.
2. Bartlett RR, Dimitrijevic M, Mattar T, Zielinski T, Germann T, Rude E, et al. Leflunomide (HWA 486), a novel immunomodulating compound for the treatment of autoimmune disorders and reactions leading to transplantation rejection. Agents Actions 1991;32:10-21.
3. Ogawa T, Inazu M, Gotoh K, Hayashi S. Effects of leflunomide on glomerulonephritis induced by antibasement membrane antibody in rats. Agents Actions 1990;31:321-8.
4. Smith-Long L, Glaser B, Weimer LK, Miller ST, Robertson SM, Aoki KR, et al. Efficacy of novel immunomodulators leflunomide and rapamycin in autoimmune uveitis. FASEB J 1992;6:A1048.
5. Xiao F, Chong AS-F, Bartlett RR, Williams JW, Leflunomide: a promising immunosuppressant in transplantation. In: Thompson AW, Starzl TE, editors. Immunosuppressive Drugs. Developments in anti-rejection therapy. London: Edward Arnold, 1994;203-12.
6. Mladenovic V, Domljan Z, Rozman B, Jajic I, Mihajlovic D, Dordevic J, et al. Safety and effectiveness of leflunomide in the treatment of patients with active rheumatoid arthritis. Results of a randomised, placebo-controlled, phase II study. Arthr Rheum 1995;38:1595-603.
7. Bartlett RR, Anagnostopulos H, Zielinski T, Mattar T, Schleyerbach R. Effects of leflunomide on immune responses and models of inflammation. Springer Sem Immunopathol 1993;14:381-94.
8. Bartlett RR, Zielinski T, Campion G, Musikic P, Schleyerbach R, Schorlemmer H-U. Chapter 20: Leflunomide: A novel immunomodulatory drug. In: Lewis AJ, Furst D, editors. Non-Steroidal Anti-Inflammatory Drugs II. New York: Marcel Dekker, 1994:349-66.
9. Zielinski T, Muller HJ, Schleyerbach R, Bartlett RR. Differential effects of leflunomide on leukocytes: inhibition of rat in vivo adhesion and in vitro oxidative burst without affecting surface marker modulation. Agents Actions 1994;41:C276-8.
10. Mattar T, Kochhar K, Bartlett RR, Bremer EG, Finnegan A. Inhibition of the epidermal growth factor receptor tyrosine kinase activity by leflunomide. FEBS Lett 1993;334:161-4.
11. Nikcevich DA, Finnegan A, Chong ASF, Williams JW, Bremer EG. Inhibition of interleukin 2 (IL-2)-stimulated tyrosine kinase activity by leflunomide. Agents Actions 1994;41:C279-82.
12. Zielinski T, Zeitter D, Mullner S, Bartlett RR. Leflunomide, a reversible inhibitor of pyrimidine biosynthesis? Inflamm Res 1995;44 Suppl 2:S207-8.
13. Williamson RA, Yea CM, Robson PA, Curnock AP, Gadher S, Hambleton AB, et al. Dihydroorotate dehydrogenase is a high affinity binding protein for A77 1726 and mediator of a range of biological effects of the immunomodulatory compound. J Biol Chem 1995;270:22467-72.
14. Pitzalis C, Kingsley GH, Covelli M, Meliconi R, Markey A, Panayi GS. Selective migration of the human helper-inducer memory T cell subset: confirmation by in vivo cellular kinetic studies. Eur J Immunol 1991;21:369-76.
15. Haynes BF, Hale LP, Patton KL, Martin ME, McCallum RM. Measurement of an adhesion molecule as an indicator of inflammatory disease activity. Arthr Rheum 1991;34:1434-43.
16. Springer TA. Adhesion receptors of the immune system. Nature 1990;346:425-33.
17. Carlos TM, Harlan JM. Leukocyte-endothelial adhesion molecules. Blood 1994;84:2068-101.
18. Oppenheimer-Marks N, Davis LS, Brogue DT, Ramberg J, Lipsky PE. Differential utilization of ICAM-1 and VCAM-1 during the adhesion and transendothelial migration of human T lymphocytes. J Immunol 1991;147:2913-21.
19. Oppenheimer-Marks N, Lipsky PE. The role of cell adhesion in the evolution of inflammatory arthritis. In: Wegner CD, editor. Adhesive Molecules. London: Academic Press, 1994: 141-61.
20. Hynes RO. Integrins: versatility, modulation and signaling in cell adhesion. Cell 1992;69:11-25.
21. van Seventer GA, Newman W, Shimizu Y, Nutman TB, Tanaka Y, Horgan KJ, et al. Analysis of T cell stimulation by superantigen plus major histocompatibility complex class II molecules or by CD3 monoclonal antibody: co-stimulation by purified adhesion ligands VCAM-1, ICAM-1, but not ELAM-1. J Exp Med 1991;174:901-13.
22. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthr Rheum 1988;31:315-24.
23. Mueller J, Brown del Re G, Buerki H, Keller HU, Hess MW, Cotier H. Nonspecific acid esterase activity: a criterion for differentiation of T and B lymphocytes in mouse lymph nodes. Eur J Immunol 1975;5:270-4.
24. Rothlein R, Springer TA. The requirement for leukocyte function-associated antigen 1 in homotypic leukocyte adhesion stimulated by phorbol ester. J Exp Med 1986;163:1132-49.
25. Potocnik AJ, Kinne R, Menninger H, Zacher J, Emmrich F, Kroczek RA. Expression of activation antigens on T cells in rheumatoid arthritis patients. Scand J Immunol 1990;31:213-24.
26. + cells from synovial fluid, synovial tissue and peripheral blood of patients with inflammatory arthritides. Scand J Immunol 1989;29: 631-9.
27. Patarroyo M. Leukocyte adhesion in host defence and tissue injury. Clin Immunol Immunopathol 1991;60:333-48.
28. Sanders ME, Makgoba WM, Sharrow SO, Stephany D, Springer TA, Young HA, et al. Human memory T lymphocytes express increased levels of three cell adhesion molecules (LFA-3, CD2 and LFA-1) and three other molecules (UCHL 1, CDw29 and Ppg-1) and have enhanced IFN-γ production. J Immunol 1988;140:1401-7.
29. Hemler ME, Glass D, Coblun JS, Jacobson JG. Very late activation antigens on rheumatoid synovial fluid T cells: association with stages of T cell activation. J Clin Invest 1986;78:696-702.
30. Locey BJ, Rogers CM, Todd RF. The role of CD11/CD18 integrin molecules in neutrophil and monocyte homotypic adhesion. In: Knapp W, Dorken B, Gilks WR, Rieber EP, Schmidt RE, Stein H, von dem Borne AEGK, editors. Leukocyte Typing IV. White Cell Differentiation Antigens. Oxford: Oxford University Press, 1989:555-8.
31. Dustin ML, Springer TA. Role of lymphocyte adhesion receptors in transient interactions and cell locomotion. Ann Rev Immunol 1991;9:27-66.
32. Pardi R, Inyerardi L, Bender J. Regulatory mechanisms in leukocyte adhesion: flexible receptors for sophisticated travellers. Immunol Today 1992;13:224-30.
33. Hogg N, Berlin C. Structures and function of adhesion receptors in leukocyte trafficking. Immunol Today 1995;16: 327-30.
34. Pavlovic MD, Colic M, Pejnovic N, Tamatani T, Miyasaka M, Dujic A. A novel anti-rat CD18 monoclonal antibody triggers lymphocyte homotypic aggregation and granulocyte adhesion to plastic: different intracellular signaling pathways in resting versus activated thymocytes. Eur J Immunol 1994;24: 1640-8.
35. Patarroyo M, Makgoba MW. Leukocyte adhesion to cells: molecular basis, physiological relevance and abnormalities. Scand J Immunol 1989;30:129-64.
36. Hibbs ML, Xu H, Stocker SA, Springer TA. Regulation of adhesion to ICAM-1 by the cytoplasmic domain of LFA-1 integrin beta subunit. Science 1991;251:1537-42.
37. Burn P, Kupfer A, Singer SJ. Dynamic membrane-cytoskeletal interactions: specific association of integrin and talin arises in vivo after phorbol ester treatment of peripheral blood lymphocytes. Proc Natl Acad Sci USA 1988;85:497-501.
38. Koopman G, Kooyk Y, de Graaf M, Meijer CJLM, Figdor CG, Pals ST. Triggering of CD44 antigen on T lymphocytes promotes T cell adhesion through the LFA-1 pathway. J Immunol 1990;145:3589-93.
39. Pals ST. CD44, a family of molecules involved in lymphocyte activation and inflammation. Rheumatol in Europe 1995;24: 35-7.
40. Lub M, van Kooyk Y, Figdor CG. Ins and outs of LFA-1. Immunol Today 1995;16:479-83.